Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Body weight-adjusted antiplatelet dosing in chronic coronary syndrome
NL-OMON59197Phase 4Recruiting
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of clopidogrel, prasugrel and aspirin in Chronic Coronary Syndrome (CCS) (3 arms), sponsored by St. Antonius Ziekenhuis. Primary endpoint: Platelet reactivity. Started Nov 2024; status: recruiting.
02
Drugs
clopidogrelprasugrelaspirin
03
Conditions
Chronic Coronary Syndrome (CCS)
Beyond the preview
Go deeper on NL-OMON59197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59197.